Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC Reply

被引：0
|
作者：
Cho, Byoung C. [1 ]
Sethi, Seema [2 ]
Spira, Alexander I. [3 ]
机构：
[1] Yonsei Univ, Coll Med, Seoul, South Korea
[2] Janssen Res & Dev, Spring House, PA USA
[3] Virginia Canc Specialists, Fairfax, VA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2025年 / 392卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：620 / 621
页数：2
相关论文
共 50 条
  • [1] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
    Rosenfeld, Roberto
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (06): : 619 - 620
  • [2] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
    Cho, Byoung C.
    Lu, Shun
    Felip, Enriqueta
    Spira, Alexander I.
    Girard, Nicolas
    Lee, Jong-Seok
    Lee, Se-Hoon
    Ostapenko, Yurii
    Danchaivijitr, Pongwut
    Liu, Baogang
    Alip, Adlinda
    Korbenfeld, Ernesto
    Mourao Dias, Josiane
    Besse, Benjamin
    Lee, Ki-Hyeong
    Xiong, Hailin
    How, Soon-Hin
    Cheng, Ying
    Chang, Gee-Chen
    Yoshioka, Hiroshige
    Yang, James C. -H.
    Thomas, Michael
    Nguyen, Danny
    Ou, Sai-Hong I.
    Mukhedkar, Sanjay
    Prabhash, Kumar
    D'Arcangelo, Manolo
    Alatorre-Alexander, Jorge
    Vazquez Limon, Juan C.
    Alves, Sara
    Stroyakovskiy, Daniil
    Peregudova, Marina
    Sendur, Mehmet A. N.
    Yazici, Ozan
    Califano, Raffaele
    Gutierrez Calderon, Vanesa
    de Marinis, Filippo
    Passaro, Antonio
    Kim, Sang-We
    Gadgeel, Shirish M.
    Xie, John
    Sun, Tao
    Martinez, Melissa
    Ennis, Mariah
    Fennema, Elizabeth
    Daksh, Mahesh
    Millington, Dawn
    Leconte, Isabelle
    Iwasawa, Ryota
    Lorenzini, Patricia
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (16): : 1486 - 1498
  • [3] Safety and tolerability of lazertinib and in combination with amivantamab in advanced EGFR-mutated Japanese NSCLC
    Goto, Koichi
    Hida, Toyoaki
    Funami, Nobuyuki
    Iwasawa, Ryota
    Mita, Sachiko
    Yamashita, Aimi
    Imanaka, Keiichiro
    Kitani, Sumiko
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2021, 32 : S317 - S317
  • [4] The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC
    Oh, Seung Yeon
    Park, Sewon
    Lee, Seoyoung
    Lee, Eun Ji
    Kim, Tae Ho
    Choi, Su-Jin
    Park, So Young
    Kim, Jae Hwan
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    Hong, Min Hee
    Yun, Mi Ran
    CELL REPORTS MEDICINE, 2025, 6 (02)
  • [5] Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2
    Lee, S. -H.
    Cho, B. C.
    Spira, A. I.
    Ou, S. -H. I.
    Waqar, S. N.
    Shah, S.
    Trani, L.
    Chu, P. -L.
    Thayu, M.
    Knoblauch, R. E.
    Bauml, J. M.
    Marmarelis, M. E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S146 - S147
  • [6] A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC
    Goto, K.
    Hida, T.
    Funami, N.
    Iwasawa, R.
    Mita, S.
    Botilde, Y.
    Yamashita, A.
    Inoh, Y.
    Haddish-Berhane, N.
    Xie, J.
    Roshak, A.
    Knoblauch, R. E.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S344 - S345
  • [7] Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2
    Cho, Byoung Chul
    Wang, Yongsheng
    Felip, Enriqueta
    Cui, Jiuwei
    Spira, Alexander I.
    Neal, Joel W.
    Baik, Christina
    Marmarelis, Melina Elpi
    Ichihara, Eiki
    Lee, Jong-Seok
    Lee, Se-Hoon
    Yang, James Chih-Hsin
    Michels, Sebastian Yves Friedrich
    Anastasiou, Zacharias
    Curtin, Joshua C.
    Lyu, Xuesong
    Leconte, Isabelle
    Trani, Leonardo
    Baig, Mahadi
    Tomasini, Pascale
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
    Ramalingam, S. S.
    Vansteenkiste, J.
    Planchard, D.
    Cho, B. C.
    Gray, J. E.
    Ohe, Y.
    Zhou, C.
    Reungwetwattana, T.
    Cheng, Y.
    Chewaskulyong, B.
    Shah, R.
    Cobo, M.
    Lee, K. H.
    Cheema, P.
    Tiseo, M.
    John, T.
    Lin, M-C
    Imamura, F.
    Kurata, T.
    Todd, A.
    Hodge, R.
    Saggese, M.
    Rukazenkov, Y.
    Soria, J-C
    Boyer, Michael
    Lee, Chee
    Hughes, Brett
    O'Byrne, Kenneth
    Briggs, Peter
    Milward, Michael
    John, Thomas
    Demedts, Ingel
    Vansteenkiste, Johan
    Bustin, Frederique
    Barrios, Carlos Henrique
    Timcheva, Constanta
    Butts, Charles
    Goss, Glenwood
    Juergens, Rosalyn
    Leighl, Natasha
    Cheng, Susanna
    Burkes, Ronald
    Zhou, Caicun
    Zhang, Helong
    Shu, Yongqian
    Cheng, Ying
    Zhou, Qing
    Li, Wei
    Feng, Guosheng
    He, Yong
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 41 - 50
  • [9] Comparing subcutaneous vs intravenous amivantamab with lazertinib in EGFR-mutated advanced NSCLC: Analysis of Asian patients from PALOMA-3
    Lee, S-H.
    Akamatsu, H.
    Yang, J. C-H.
    Lim, S. M.
    Liu, B.
    John, T.
    Wang, J.
    Ohe, Y.
    Kondo, M.
    Tamiya, M.
    Danchaivijitr, P.
    Hsu, P-C.
    Zhuo, J.
    Saadoun, C.
    Saxena, N.
    Balaburski, G.
    Ribeiro, L.
    Gamil, M.
    Baig, M.
    Cheng, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1634 - S1634
  • [10] EGFR-TKI plus /- Antiangiogenics for EGFR-mutated Advanced NSCLC
    da Silva, L. L.
    Matsas, S.
    Aguiar, P., Jr.
    Taveira, G. M. T.
    Barcelos, I. F.
    Lopes, G. L., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S417
12345